Gilead Sciences (NASDAQ:GILD) Upgraded to "Outperform" at Daiwa Capital Markets

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Daiwa Capital Markets upgraded shares of Gilead Sciences (NASDAQ:GILD - Free Report) from a neutral rating to an outperform rating in a report issued on Tuesday morning, Marketbeat reports. They currently have $128.00 price objective on the biopharmaceutical company's stock.

A number of other research firms have also weighed in on GILD. Morgan Stanley upped their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Truist Financial upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and boosted their price target for the stock from $108.00 to $127.00 in a report on Friday, August 8th. Royal Bank Of Canada increased their price objective on shares of Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research report on Friday, August 8th. Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price objective on the stock. Finally, Needham & Company LLC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price for the company in a research note on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $115.39.

Gilead Sciences Stock Down 2.2%

Shares of NASDAQ GILD traded down $2.59 during mid-day trading on Tuesday, hitting $116.14. The company had a trading volume of 6,062,069 shares, compared to its average volume of 6,678,418. The company has a market capitalization of $144.11 billion, a PE ratio of 23.14, a price-to-earnings-growth ratio of 0.73 and a beta of 0.33. The business's 50-day simple moving average is $112.41 and its 200 day simple moving average is $108.90. Gilead Sciences has a 1-year low of $75.35 and a 1-year high of $121.83. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. During the same period in the previous year, the firm posted $2.01 EPS. Gilead Sciences's revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, analysts predict that Gilead Sciences will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is 62.95%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $113.94, for a total transaction of $1,139,400.00. Following the transaction, the chief executive officer owned 605,725 shares of the company's stock, valued at approximately $69,016,306.50. This trade represents a 1.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the business's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $109.74, for a total value of $548,700.00. Following the completion of the sale, the director directly owned 8,920 shares of the company's stock, valued at $978,880.80. The trade was a 35.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock valued at $9,339,230 over the last quarter. 0.27% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in GILD. Smallwood Wealth Investment Management LLC purchased a new position in Gilead Sciences during the 1st quarter worth $25,000. Activest Wealth Management boosted its stake in shares of Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 227 shares during the period. GoalVest Advisory LLC boosted its stake in shares of Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 227 shares during the period. Harbor Asset Planning Inc. purchased a new position in shares of Gilead Sciences during the second quarter worth about $27,000. Finally, Goodman Advisory Group LLC acquired a new position in Gilead Sciences in the 1st quarter valued at about $29,000. Institutional investors and hedge funds own 83.67% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.